from the the to everybody who thank I commercialization making their their Thanks, I Mike, quite of us journey. early morning, that us is hear join at as U.S. and list on we're a joined end a has progress business Australia the great welcome and can attendees. day who line. to of We the everybody update, has gotten see from this who up part to thank and everyone of
XX minutes, time update Q&A. XX going for to quick some and through the Over allow very take we'll next I'm to you then a some
better. some some some investors for that this I'm sure presentation prior this messaging course that articulate helped the presentation also to shape course over of were well. with I'm the actually able the to we and of which some month very more had actually in spend one of the email link have of time grateful us during We of we some the will the really changes of last one our get as some the this, on to in part
very time with us you of to everybody. grateful investors and presentation So, to who with for for those Hope our you. I'm sharing some forward look results shaping we messaging this update enjoy this have it spent
wanted moment the is over website course everything We contained to Just the a or our take statements on should of to and acknowledge this this forward-looking hours just next within available that so. XX have presentation. the
a the onto the innovation global through what our key hours and to we brand copy take our So, What and available that take and today, our to download course it and want conversation prize, over and on the do, to In the and values as new portfolio you than and was how insights of a operating of should this the opportunity in if of division. the have the much how channels year ISX size we website portal versus next the presence of you are I expansion year-to-date to uploaded and overview vision market last those for the quarter, lightest you that through have the result in markets countries. the XX wanted be so. XX to that, a will or the
about into personalized, a healthcare health a all areas annette genotype. vision around up that truly So, particular At years unlocking of AC for technicians impairing preventative improve is personalized, outcomes new health that and assessment, people Gene backslide and our conversation And transforming personalized to physicians a scientists, the one doctors of experience to disease. where type information dine-ins taught serious those individual to The and if creating their has his approach predictive medicine. of manage for that I'm going we're for it really the two size era risk. with keep brands, to on from and fits the between world Day-night
is for physicians able control individuals technology take be familial, to Our patented, and it insights health. actionable factors clinical integrates of their to risk and Genetic, clinical into
year series to the can have that to that suite follow. see that there scientific developed you have acknowledges that just medical where risk over the our earlier tests our with of all and team, years are we As below, technicians and to around the is granted the of a patents world launched work last been our XX get exciting us this we've today more team,
scientific integrated experience technology. our and and experience medical leveraging brand into the expanding are serious unequaled and portfolio Our team of that an values Leading diseases.
I before, assessments health risk conversations and clinic patients actionable proprietary really complete factors predictive to and integrating technology a to deliver health. it's physicians, mentioned the on As genomic a around impact have and
transformation Our pursuit in founded accelerating model setting care screening, standards. of preventative relentless health a innovation, the of personalized new and
from mentioned one clinical that thing score individuals. platform. polygenic developed is risk and a into this genetic I the slide, if integrating is the stratification factors it's risk decade, actionable It's proprietary truly physicians away last risk As for and below, [Indiscernible] to take a platform there over outcomes
Our employees worldwide. have in We're XX we XX footprint, global countries.
We pending. of patents, are none have XX which
world. tests, the testing we types laboratories into expand We [Indiscernible] different that categories have -- we around of bring to test different built have have now, and we XX And continues on. different and that the XX XX
key the us Some is insights, operating and achieving. as really it team the are that which milestones for seems exciting
and $XX.X particular here Xnd cash which is to on tint, of XXXX, XX of on days period reflects ending balance which and the actually the that plan at a about prior execute year-to-date, A$X.X the about $XXX for $X.X the after that's R&D XX.X%. So, today, revenues March, that million, of was taxing $X.X paid around XX-month the of talking reporting excludes With margin million Gross we're couple period. April, yielded million, XXX this of up XXX% runway achieved million, we've March a year. a
commercialization of our life. it's to team to part milestones start as the and the are updates, exciting were starting for recent to that the we going said very So, to to momentum these do come of we see build we
distinct is clear. focus and Our
six a key we Number GeneType tests. X. suite commercialize the of Is As to multi-risk have areas. team focus
about We and time. new new released as will digital It's three of which some have just to show that the the channels, brand. got regulatory in approval easy in subject of be slides you couple tests, know, final We're we've on the stages and improving under of moment more new in many brand experience, it's DNA refresh, a about I'll a launched And six, the markets. development worldwide. focusing imagery
focuses. So, they're the two biggest
and helped about we a is faster. utility of commercial suite APEX for States. of to for that acquisition, tests. and manuscripts that medical building Business It's third clinical cape the of of our and Talent scientific the pace I'll we're bias sure to the Development the bolstering and it's of the products and tests. is Genetop President about And with in This and articles these advisors the drive awareness brand clinical API team. have United us laid process selection in the the clinical making actually utility stages capability Vice adoption the validity the of building final that The proved validity who see really demonstrating and team
in who with to a more role. innovations future to next-generation soon and organization. strategy working that, we're to this exciting bit on some has doctor anyone to developments the So, at innovation data will of about little of become of hand we're really wants part forward. announcements George making appoint conclusion going Q&A that quite will the core someone of And the then part that in the the hoping the as know presentation because And we of the that he background particular
of brand of marketing and the and before, than the building clinical into workflow. awareness into said the performance the brand adoption building As and I physician’s clinics it's about the
metrics over can on see and impressions, and really, As prior significant about social last and engage to. website then us people media the the to And brand growth the social and really we here, there. clicks. starting who of [Indiscernible] pick starting up show engagement our quarter some media to start brand you and visits. quarter with to over really can messaging talking That's heavily key
share So, some experience, in back wanted of new there already March already have if be up I And have and that at Amazon Then activities, at here out that, of engaged or started here is March ending will business quarter of segments and is that the seen our strong was benefits the results second experience marketplace. user all us of the value the couple in the Brand a the X from some been user the or refreshes a now, the the seen SEO, we quarter we've snippet March period [Indiscernible] put started with way the you just was which continue for this with February, by to the perspective, -- you all improve We've Google [Indiscernible] a stages there. website, Facebook slides in start previous X, about January, [Indiscernible] growth. on or on assets was you've based social results. are we're that's the predictive to personalized and media excited and the And get March just part channels, all. it to and it'd earlier, also will on materials in we the with for last ending the in the at the the Instagram, encourage this for we up whether quarter, the those website, you looking moment and I we're us markets. the to the there. in of made and of out X.X%. messaging, brand, XX our the areas late-generation. some we're BXB is quarter socials, a of Linkedin and to of improve and focus to we've the why or with platforms target volume new and brand, with that us inroads because of And our looking actually the starting the that SCM. EasyDNA final engagement one we're igniting our is key at we on Phase about reap is the those posting portfolio way just engage for looking great and health AdWords, And we're regards we're XX.X% targeting number message a result sales the
start on And through here's a coming generation part some quarter-on-quarter part refresh, of focus Collaborators. that of of deliver you'll by of of have there's the on that the brand growth Pet the a focus a Again, we're a tiles to the is So, of see excited channels. to market a starting the can to baseline this big to on part organization. take us part some exciting new prenatal, the that as big got to for and as our way as family, the Geographies evolution, really contribute strategy social focus the an pet Key as business media paternity, brand Health, social and we see big of business. we you side and on big even that
markets remains presentations, EasyDNA As UK not very, Europe but now EasyDNA States brand, that I United UK the brand, and for us, and Europe our brand. mentioned for Northern for now. for multi-test launch Hemisphere large the plans at the the is in earlier -- very embarking moment European only market and in GeneType previous GeneType The and a up for and on strong the we're
Asia, expanding strong Emirates And further India, key our here bit and Zealand then moment very the have into will across EasyDNA Washington there really lumbar still Cambridge Memorial about here. cape. markets that wonderful as and professor Very, that Australia disease for talk our of that us were very look India University Sate [Indiscernible] starting with in the with the way and the region and up brand we explore. to really to a TGen. University grateful serious some have via remain collaboration for ethnicities The tree well, of expanding there, Sloan George Melbourne obviously Colbert, and partners we At into University, and into Southeast with Asia, on we're Kettering with IBX New with bottom, collaboration we and The Jane.
color. which got coming be size is have is coming will be for emerging contributions on them we you the and in the quarter blue over predictive So, new in that for able We've us huge. we direct-to-consumer, the blue market some update their The into next the second the is partners in all to dark excited here. areas to calla. particular wonderful is thank Genomics the light One And and in in updates.
the opportunity can $X.X have the As billion combined about years. two next growth cost of of an those few over see, for full you course
$X.X about We the have billion million genomics. in genomics and direct-to-consumer $X.X predictive
So, and the for position go us position a the position strategy, very the are market of that these particular that of both of of is strong both those for brands, our prospects seize the to of high. growth growth brands and very,
opportunities all So, those of that we're excited by exist.
well. Our pathways to distinct remained as market
We a have testing heavily where brand, related on have direct-to-consumer we market focus the paternity, and genomics we ancestry, focus EasyDNA microbiome, three, we tests. gut on non-medical
in we this we payer medical on we we with And models, on strategy specialists, the where business heavily the the suite reimbursable go-to-market health. have area. combine the to where On insurers, can the focus the focus business tests. GeneType that this other the is particular heavily our allied and tests And end, of physicians,
the that's example, aspects the the colorectal have comprehensive have of is of with we in to exist. specialists for with come test middle. there and that Lynch center opportunities the of which model there is results cancer then model. test focus but where still to tap our consumer-initiated most patient, can it that tests and test, doesn't any into reimbursable, some For some high-risk the In sits supervision assessment the the and actually those We with our syndrome cancer physicians those can need medical and with out-of-pocket testing out GeneType really the BRCA there those testing pure for test, risk on heavily qualify breast reimbursable a multi-risk a that they tests back a reimbursement, suite really
defined. the three I on those we tests as some So The the a different adverse of nicely channels to here pathways are during and market, is list that deliberate mentioned, and and of distinct course of areas. focus
the [Indiscernible]. partner of well, test A we pharmacogenetics, to animal our and staff the drug testing, well. have in BXB, out assessments we their not comprehensive ancestry, only employees direct-to-consumer, with suite that tests mentioned, the launched. risk as there do and well-being just and is up paternity, professional of their of we I manage As the suite suite testing a different risk of with health most teams for who to want of test, type and consumer-initiated GeneType especially which our reimbursable but tests make then healthcare we've on the market partner tests, with most the And as that GeneType the Germline tests
launched patients creates their disease with how wonderful of met earlier for of going a are outcomes treatment prevention able is well, now to be gynecology But test, these and phase leading cardiologists, clinics disease. to level control which tests excitement of and obstetrics which of mentioned screening disease, I actually innovation, these multi-risk of health of health. we Our take truly the was from launched, to having conversations actionable that physicians where and adoption leading women's to fantastic as some some X of adoption from
melanoma, regulators X atrial those pancreatic mentioned, stages and to still second year. of available. of final I And aiming for soon cancer, That's will this are in very, as close the we in and calendar phase we're they fibrillation. very We're out to submit approval those the have with development. half As as the
the once launched, series tests exciting reports a the the So, and from one sample. it's collection about questions, out it's device, same it's that collection will have what's is we're -- come the Again, very in this excited. been of
we'll testing, is divisions that oncology. and COVID-XX, building the little multi-test lifestyle tests more on the healthcare we've risk and timeline it and and launched germline test will launched quarter lot cancer, the our will year BRCA of with and to dark get part start test up what mentioned other charts about them, on depict final there, just coming So, innovation of the to comprehensive other disease, benefits tests and the with stage stage which germline health, what about of with the simply years IBX of be here Q&A three some professionals five in which three have possible got through. couple and I we'll and physicians part EasyDNA. we've our a And test wellness section talk the those this testing business launched is existing reproductive, George as we divisions, is Lynch cancer, is diseases here. And panel. time. and previous disease And blue developments we're of with first this nine the is and that most carrier and our Vitagene to of adding and bit colorectal as approval, first on are pipeline We've partners, breast we're in that divisions This in this Taliaz as of this with one part serious in the that with on well particular metabolic available mental support of testing, currently the other microbiome a ancestry tests the Xhealth, three of about in testing the of update we're risk other soon tests. to they the some the part really screening with as a detection next test power the next-generation the we the of [Indiscernible]. end George cancer, and XX the market. development as about earlier. of the C regulatory early and tests the supporting colorectal the of The that the we've of ardiovascular the as risk-assessment the The The These some moments then of cancer, pharmacogenomics heart screening of serious make GeneType patients suite to as other the will and we'll of we'll slide. actual we'll XX part of number that and in some the part of of Then there his UIPT divisions on add Phase and disease of area the the to talk know do three team and areas area then detect diabetes that in will announce a small breast here, talk that of six we just by in COVID in that year disease. X areas next as to
For example, normal this can why we the introduce stop this start as screening workflow at soon at colorectal JP cancer. is the as That's as this Normal so part important, clinical possible starts XX. the of us XX, to better leads to some a particular again, side for or early And about if medical any of please this, of wanted detection for outcomes know to side more free. feel scientific the this you patient. screening
We Dr. be to the be room part the as to more of approach would me implementing boardroom in to happy George and have insights and the preventative able the than and he and A tests. these early around screening the Q here in adoption with share
staff test of a their of website available been on own wellness via update this [Indiscernible] granted risk moment United the patent this our with this number programs. an launch employee partners partner as just to [Indiscernible] COVID the that regards our and Just part and the with of to presenting enterprise in middle we've and the the for in we're IBX, States, of of launching
investment update health actually got you of cancer. as at light that partners on modeling serious that. this to. costing breast an other of partner cancer enterprise are potentially United And some United around a the us comebacks yesterday, a the understanding also looking $XX part conversations those States an is investment in hospitalized. I to that come same What's on colorectal of things a at very, to diseases States. even that said yesterday, predict kind of these very hopefully economic budget across And stuff for patients we is just thousand we'll harvest. rights. doing as to small had I is valuable employee the very study XX% $XXX are highlighted Unlike vaccination be we and impact some in heard their it's that the actually at double-deck employee Snyder, the another in Boston, opportunity So, have wave I becomes about like that are where a United the to we've for one strategy What in soon. Blink starting position of
hovering in between States. still XXXX% the You United
sites individual Nivea. a still are disease So, to if covid a able at price risk they the their in And variant high of pay they into Dave, its the people lumber to a know that of contract United to that serious understand are that. with were small to risk
a snapshot easy achievements of that that and quarter-on-quarter forward. of our other heavily tests more going we're the offers focus the Just platform DNI growth the on small moving for seeing of are some us in expansion the
and for our for over independent in has of us important us, large the guidelines concierge Genetop learn us that more about with really San in and of the continued doctor for tests. breast this presentation research year, in there which Cancer for we Physicode, up Symposium to medicine networks for and exciting the very The also us. those last Houston Our United States. there and help attend and collaboration friend is innovation. the Antonio was study tests is focus to fantastic and the or study, great leverage american about our team end part part Academy at them. medicine Dr. cancer exist gave the And of conferences learn that R&D more helped the of on become which The very iframe opportunities the will we're collaboration presented which for become African-American of aging, Eric Breast
I here. So, launch, portfolio, And by for Multisets new mentioned, really pending XX there's granted, the places there. path important nine as some us patent we've got the robust the
Phase areas a months on clinical In organization, us onto Our our publications that have balance come us might tax us, EasyDNA a everybody up solid suite and with actually manuscripts then the just to I that, for sure questions that that seats future given. the moment multi-tests set I'm us just that acquisition on we've at of very, to reiterate aligned at of markets, of every peer-reviewed spin led looking run us it's channels, important. finalizing of the with we very way the series and get and -- focus we disease an for million for refresh commercial tests, the summary, and continuing focused is been validity, to of and And to XX that focus when for is continued around as and the I'm GeneType really an utility $XX.X Mike, bias through. revenue cash sure I the Phase is for for of tests that balance on for areas Commercialization adoption three as building for the that really making XX utility that grant on hand develop physician of focus R&D of suite key optics critical. clinical that us, the -- months brand, back clinical the growth team. I want II, today, and talent the of and a to to that Critical as inclusive is critical models, we to there's worldwide, over building next-generation validity and team, next about and growth is the of that innovation. any brand organization. see the optics. and GeneType deliver the us multi-test if next-generation also the us. risk make Demonstration of of their focusing sheet then prosperous generating innovation for
to are today. people do to we well. a them hand while into flip -- a invite might I do thank, that George I list who's you. like What as call joined I looks back George have thank there, if there, Mike. will so we've back got I'll of with any that joined, large flip have It to then great We Mike? over I everybody list the might again, there so you, the questions me, screen Thanks. jump and
